电针治疗萨尔科佩尼亚:随机对照试验的研究协议
Hao Li1,2, Li Zhou3, Xin Zhang1
1Division of internal Medicine, Institute of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
BMC complementary medicine and therapies
|December 28, 2024
概括
电针 (EA) 显示出对治疗肉症的希望,这种疾病的标志是与年龄相关的肌肉损失. 这项研究调查了EA的研究.
科学领域:
- 老年学是一门学科.
- 物理医学和康复 康复
- 整合和补充医学是整合和补充医学.
背景情况:
- 萨科佩尼亚的特点是与年龄相关的骨肌肉质量,力量和身体表现的损失,老年人中增加了跌倒和残疾风险.
- 有限的临床干预措施存在于sarcopenia,构成一个显著的医疗负担.
- 这项研究探讨了电针 (EA) 作为对的潜在治疗方法.
研究的目的:
- 评估电针 (EA) 的临床疗效和安全性,用于治疗患有症的老年患者.
- 在一个随机的,假的受控试验中,将EA治疗与假电 (sEA) 进行比较.
主要方法:
- 总共有168名老年肉症患者被随机分配 (1:1) 接受EA或sEA八周,每周三次.
- 这些针点包括LI4,LI10,LI11,LI14,ST32,ST34,ST36和ST41.
- 主要结局是抓地力 (GS) 的变化;次要结局包括4周和20周的抓地力,尾骨肌肉质量指数 (ASMI),短物理性能电池 (SPPB) 评分和身体活动水平 (IPAQ).
主要成果:
- 这项研究旨在测量握力,肌肉质量,身体表现和身体活动水平的变化.
- 患者的期望,主观疗效和盲目的疗效也将被评估.
结论:
- 这项随机对照试验的进一步结果正在等待.
- 这些发现将有助于开发针对肉症的新型干预措施.
相关概念视频
02:07Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
01:11Blinding
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...